All lobbying filings

DLA Piper LLP (US)

DLA Piper LLP (US) filed a Q3 report for Biotechnology Innovation Organization on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for Biotechnology Innovation Organization · Advocacy organization for the biotechnology industry.

As filed: DLA PIPER LLP (US) for BIOTECHNOLOGY INNOVATION ORGANIZATION.

All filings by DLA Piper LLP (US) · Everything Biotechnology Innovation Organization has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Pharmacy

340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.

Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

Health Issues

Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.